^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    risvutatug rezetecan (GSK5764227)

    i
    Other names: GSK5764227, HS-20093, HS20093, HS 20093, GSK 5764227, GSK-5764227, GSK’227, ris-rez
    Associations

    News

    Trials
    Company:
    GSK, Jiangsu Hansoh Pharma
    Drug class:
    Topoisomerase I inhibitor, B7-H3-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    8d
    A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (clinicaltrials.gov)
    P3, N=494, Not yet recruiting, Hansoh BioMedical R&D Company
    New P3 trial
    |
    paclitaxel • docetaxel • irinotecan • risvutatug rezetecan (GSK5764227)
    14d
    300640: A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) (2025-523997-18-00)
    P1/2, N=14, Not yet recruiting, Glaxosmithkline Research & Development Limited
    New P1/2 trial
    |
    risvutatug rezetecan (GSK5764227)
    19d
    A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) (clinicaltrials.gov)
    P1/2, N=184, Not yet recruiting, GlaxoSmithKline
    New P1/2 trial • Pan tumor
    |
    CD276 (CD276 Molecule)
    |
    Idafang (ivonescimab) • risvutatug rezetecan (GSK5764227)
    19d
    PanTumor-101: A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) (clinicaltrials.gov)
    P1, N=845, Recruiting, GlaxoSmithKline | N=590 --> 845 | Trial completion date: May 2027 --> Jun 2029 | Trial primary completion date: Sep 2026 --> Oct 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • Jemperli (dostarlimab-gxly) • Imdelltra (tarlatamab-dlle) • risvutatug rezetecan (GSK5764227)
    19d
    A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) (clinicaltrials.gov)
    P1/2, N=113, Not yet recruiting, GlaxoSmithKline
    New P1/2 trial
    |
    risvutatug rezetecan (GSK5764227)
    1m
    BeeHive: A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov)
    P2, N=30, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting | Trial completion date: Jun 2030 --> Mar 2031
    Enrollment open • Trial completion date • IO biomarker
    |
    Jemperli (dostarlimab-gxly) • risvutatug rezetecan (GSK5764227)
    2ms
    HS-20093-309: A Multicenter, Randomized, Open-Label, Controlled Phase III Clinical Study Evaluating the Efficacy and Safety of HS-20093 Injection Combined with Adebrelimab versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer without Actionable Genomic Alterations (ChiCTR2600121048)
    P3, N=450, Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD276 (CD276 Molecule)
    |
    PD-L1 expression • EGFR mutation • ALK fusion • ALK mutation • ROS1 fusion
    |
    docetaxel • AiRuiLi (adebrelimab) • risvutatug rezetecan (GSK5764227)
    2ms
    ARTEMIS-011: Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure (clinicaltrials.gov)
    P3, N=117, Active, not recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • docetaxel • risvutatug rezetecan (GSK5764227)
    3ms
    First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=152, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608) • risvutatug rezetecan (GSK5764227)
    3ms
    A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, Hansoh BioMedical R&D Company
    New P3 trial
    |
    docetaxel • AiRuiLi (adebrelimab) • risvutatug rezetecan (GSK5764227)
    3ms
    HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P1, N=40, Recruiting, Hansoh BioMedical R&D Company
    New P1 trial
    |
    risvutatug rezetecan (GSK5764227)
    3ms
    A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P3, N=420, Recruiting, GlaxoSmithKline | N=300 --> 420
    Enrollment change
    |
    topotecan • risvutatug rezetecan (GSK5764227)